According to Fortune Business Insights, the global allergy immunotherapy market size was valued at USD 1.99 billion in 2025 and is anticipated to grow from USD 2.17 billion in 2026 to USD 5.14 billion by 2034, exhibiting a CAGR of 11.38% during the forecast period. Europe dominated the global allergy immunotherapy market with a market share of 71.08% in 2025.
The market is witnessing strong growth due to the increasing prevalence of allergic disorders, rising awareness of long-term allergy management, growing adoption of sublingual immunotherapy, and expanding availability of treatment through hospital, retail, and online pharmacies. Continued advancements in allergen-specific therapies are further supporting market expansion.
Key Market Drivers
Increasing Prevalence of Allergic Disorders
The rising incidence of allergic rhinitis, allergic asthma, and other allergy-related conditions is increasing demand for effective long-term treatment options.
Growing Adoption of Allergy Immunotherapy
Increasing awareness of immunotherapy as a treatment approach for managing specific allergies is supporting market growth.
Rising Demand for Sublingual Immunotherapy
Growing preference for convenient and less invasive treatment options is contributing to the adoption of sublingual immunotherapy products.
Market Restraints
Long Treatment Duration
Allergy immunotherapy often requires prolonged treatment and regular patient adherence, which may affect treatment completion rates.
Risk of Adverse Reactions
Potential allergic reactions associated with immunotherapy can require careful patient selection, monitoring, and professional medical supervision.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/allergy-immunotherapy-market-100727
Market Opportunities
Development of Advanced Allergen-Specific Therapies
Continued research into improved allergen formulations and personalized treatment approaches is creating opportunities for innovative immunotherapy products.
Expansion of Retail and Online Pharmacy Channels
Increasing availability of eligible allergy treatment products through retail and online pharmacies is creating opportunities for improved accessibility.
Segmentation
By Type
- Subcutaneous Immunotherapy
- Sublingual Immunotherapy
By Application
- Allergic Rhinitis
- Allergic Asthma
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Online Pharmacies
Regional Insights
Europe
Europe dominated the allergy immunotherapy market with a market share of 71.08% in 2025. The region benefits from established allergy treatment infrastructure, strong awareness of immunotherapy, availability of allergen-specific treatment options, and the presence of companies specializing in allergy therapeutics.
North America
North America remains a significant market supported by the prevalence of allergic conditions, advanced healthcare infrastructure, and growing awareness of allergy diagnosis and treatment options.
Asia Pacific
Asia Pacific is expected to witness growth during the forecast period due to improving healthcare infrastructure, increasing awareness of allergic disorders, and expanding access to allergy diagnosis and treatment.
Rest of the World
Latin America and the Middle East & Africa are gradually increasing adoption of allergy immunotherapy as healthcare access improves and awareness of allergy management expands.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/allergy-immunotherapy-market-100727
Key Players in the Allergy Immunotherapy Market
- ALK-Abelló A/S
- Stallergenes Greer
- Allergy Therapeutics plc
- HAL Allergy Group
- LETI Pharma
- Aimmune Therapeutics, Inc.
- HollisterStier Allergy
- Jubilant HollisterStier LLC
- ASIT Biotech
- DBV Technologies
Conclusion
The global allergy immunotherapy market is expected to witness strong growth through 2034, driven by the increasing prevalence of allergic disorders, growing adoption of allergy immunotherapy, and rising demand for convenient treatment options. Continued advancements in allergen-specific therapies and expanding treatment accessibility are expected to create significant growth opportunities for market participants during the forecast period.